Skarin, A T <br/><br/>
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 1983 
 - 91-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1983.1.2.91  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Actuarial Analysis<br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bleomycin--administration & dosage<br/>Bone Marrow--drug effects<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Leucovorin--administration & dosage<br/>Lymphoma--drug therapy<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Meningeal Neoplasms--drug therapy<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Prognosis<br/>Vincristine--administration & dosage